# Melissa L. Johnson

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/melissa-l-johnson/

## Facts

| Field | Value |
| --- | --- |
| Citations | 24,937 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 67 |
| i10-index | 224 |
| Last Known Institution | Sarah Cannon Research Institute |
| OpenAlex ID | https://openalex.org/A5049294543 |
| ORCID iD | https://orcid.org/0000-0001-9874-1314 |
| Works | 859 |

## Researcher papers

- [First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer](https://scholariq.org/papers/first-line-atezolizumab-plus-chemotherapy-in-extensive-stage-small-cell-lung/)
- [Adagrasib in Non–Small-Cell Lung Cancer Harboring a <i> KRAS <sup>G12C</sup> </i> Mutation](https://scholariq.org/papers/adagrasib-in-non-small-cell-lung-cancer-harboring-a-i-kras-sup-g12c-sup-i/)
- [Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer](https://scholariq.org/papers/efficacy-of-selpercatinib-in-i-ret-i-fusion-positive-non-small-cell-lung-cancer/)
- [Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study](https://scholariq.org/papers/rovalpituzumab-tesirine-a-dll3-targeted-antibody-drug-conjugate-in-recurrent/)
- [Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer](https://scholariq.org/papers/tarlatamab-for-patients-with-previously-treated-small-cell-lung-cancer/)
- [Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1–Selected Advanced Non–Small-Cell Lung Cancer (BIRCH)](https://scholariq.org/papers/phase-ii-trial-of-atezolizumab-as-first-line-or-subsequent-therapy-for-patients/)
- [HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy](https://scholariq.org/papers/herthena-lung01-a-phase-ii-trial-of-patritumab-deruxtecan-her3-dxd-in-epidermal/)
- [MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with <i>MTAP</i> -Deleted Cancer](https://scholariq.org/papers/mrtx1719-is-an-mta-cooperative-prmt5-inhibitor-that-exhibits-synthetic-lethality/)
- [First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2–Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non–Small-Cell Lung Cancer: TROPION-PanTumor01](https://scholariq.org/papers/first-in-human-phase-i-dose-escalation-and-dose-expansion-study-of-trophoblast/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Protein Tyrosine Phosphatases](https://scholariq.org/topics/protein-tyrosine-phosphatases/)

## Researcher university

- [Sarah Cannon Research Institute](https://scholariq.org/institutions/sarah-cannon-research-institute/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.